Seizure Drugs: Adult Efficacy Data May Be Extrapolated To Pediatric Patients
US FDA final guidance on partial onset seizure drugs reflects only one major change from an earlier draft version: the lowering of the youngest age for which extrapolation of efficacy is appropriate, from four years to two years.
You may also be interested in...
US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.
Agency’s clinical experts favor granting access under regulations intended for investigational drugs but ‘lawyers want consistency under the law,’ FDA’s Woodcock says; use of the expanded access pathway for approved agents is generally unnecessary but may provide sponsors with some regulatory cover, external experts say.